Related Experiment Videos
Plasma lipid profile in verapamil-treated hypertensive patients
1Department of Nephrology, Tel Aviv Medical Center, Rokach (Hadassah) Hospital, Israel.
Insights
Verapamil treatment may worsen lipid profiles in hypertensive patients with pre-existing hyperlipidemia. Careful monitoring of triglyceride and very low-density lipoprotein levels is advised for these individuals.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Lipid Metabolism
Background:
- Hypertension is a major cardiovascular risk factor.
- Verapamil is a commonly prescribed calcium channel blocker for hypertension.
- Hyperlipidemia is often comorbid with hypertension.
Observation:
- Plasma lipid profiles were monitored in hypertensive patients over one year.
- Patients received verapamil treatment during the study period.
Findings:
- Verapamil treatment led to elevated triglyceride levels.
- Very low-density lipoprotein (VLDL) fractions also increased.
- These elevations were most pronounced in patients with pre-existing hyperlipidemia.
Implications:
- Caution is advised when prescribing verapamil to hyperlipidemic patients.
- Further research is needed to confirm these findings in larger populations.
- Potential need for alternative antihypertensive strategies in certain patient groups.
Abstract:
Plasma lipid profiles were monitored for one year in hypertensive patients treated with verapamil. Elevations of triglyceride and very low density lipoprotein fractions were demonstrated in those patients already hyperlipidemic before commencement of verapamil. Caution may be necessary when giving verapamil to these hyperlipidemic patients. Further larger studies seem warranted.